Sp740
PANEL DISCUSSION
Date
May 20, 2024
Tracks
Related Products
INTEGRIN INHIBITION REDUCES PROFIBROTIC RESPONSES IN CROHN’S DISEASE (CD) HUMAN INTESTINAL MYOFIBROBLASTS IN VITRO AND AMELIORATES EXPERIMENTAL INTESTINAL FIBROSIS IN VIVO - A POTENTIAL NOVEL APPROACH TO CD STRICTURE THERAPY
_INTRODUCTION:_ Despite effective anti-inflammatory therapies, ~70% of CD patients require surgery in their lifetime, due to fibrostenotic strictures linked to excess extracellular matrix (ECM) deposition…
VEDOLIZUMAB REDUCES IGG+ PLASMA CELLS AND FCγR SIGNALLING IN TREATMENT RESPONDERS
Vedolizumab (VDZ) is a monoclonal antibody that targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC) and Crohn’s disease, its mode of action (MOA) remains unclear…
BIOACTIVE INTERLEUKIN-1 DETECTED IN IBD PATIENT INTESTINAL BIOPSIES IS A HALLMARK OF ULCERS AND CORRELATES WITH TRANSCRIPTOMIC ASSESSMENTS, INCLUDING AN ULCER-SPECIFIC GENE MODULE ASSOCIATED WITH STROMAL CELL DIFFERENTIATION
BACKGROUND: Multiple studies have identified interleukin (IL)-1 proteins (IL-1α, IL-1β) as playing a key role in intestinal inflammation, including the expansion of IL-1 expressing cells as a hallmark of severe and anti-TNFα non-responsive inflammatory bowel disease (IBD)…